期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 7, 期 9, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a030452
关键词
-
资金
- Howard Hughes Medical Institute Medical Fellows Program
- National Cancer Institute [CA166440, R01CA168899, R01CA172382, R01CA190289]
- Prostate Cancer Foundation
- Howard Hughes Medical Institute Physician-Scientist Early Career Award
- American Cancer Society Research Scholar Award [12-038-01-CCE]
- Department of Defense PCRP award [W81XWH-16-1-0404]
The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据